Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors

European Journal of Cancer

Volumn 43, Issue 8, 2007, Pages 1318-1327

  Pandini, Giuseppe ^a   Wurch, Thierry ^b   Akla, Barbara ^b   Corvaia, Nathalie ^b   Belfiore, Antonino ^c   Goetsch, Liliane ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Hybrid receptor; IGF 1R; Ligand binding; Monoclonal antibody; Mouse xenograft model; Phosphorylation

Indexed keywords

HYBRID PROTEIN; INSULIN RECEPTOR; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17 69; MONOCLONAL ANTIBODY 1H7; MONOCLONAL ANTIBODY 24 60; MONOCLONAL ANTIBODY 29B4; MONOCLONAL ANTIBODY 47 9; MONOCLONAL ANTIBODY 7C10; MONOCLONAL ANTIBODY 83 7; MONOCLONAL ANTIBODY 9G4; MONOCLONAL ANTIBODY ALPHA INSULIN RECEPTOR 3; MONOCLONAL ANTIBODY H7C10; MONOCLONAL ANTIBODY INSULIN LIKE GROWTH FACTOR 1 RECEPTOR BETA SUBUNIT; MONOCLONAL ANTIBODY MA 10; MONOCLONAL ANTIBODY MA 20; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOTHERAPY; INSULIN-LIKE GROWTH FACTOR I; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RADIOLIGAND ASSAY; RECEPTOR, IGF TYPE 1;

EID: 34248170187     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.03.009     Document Type: Article

References (37)

1. Hofmann F., and Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10 (2005) 1041-1047
2. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92 (2005) 2097-2101
3. Werner H., and Maor S. The insulin-like growth factor-1 receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab 17 (2006) 236-242
4. Andrews D.W., Resnicoff M., Flanders A.E., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19 (2001) 2189-2200
5. Parrizas M., Gazit A., Levitzki A., Wertheimer E., and LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138 (1997) 1427-1433
6. Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
7. Li S.L., Kato J., Paz I.B., Kasuja J., and Fujitayamaguchi Y. Two new monoclonal antibodies against the subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun 196 (1993) 92-98
8. Sachdev D., Li S.L., Hartell J.S., Fujita-Yamaguchi Y., Miller J.S., and Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63 (2003) 627-635
9. Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63 (2003) 5073-5083
10. Burtrum D., Zhu Z., Lu D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63 (2003) 8912-8921
11. Goetsch L., Gonzalez A., Leger O., et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113 (2005) 316-328
12. Jackson-Booth P.G., Terry C., Lackey B., Lopaczynska M., and Nissley P. Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res 35 (2003) 850-856
13. Wang Y., Hailey J., Williams D., et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4 (2005) 1214-1221
14. Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 (2005) 2063-2073
15. De Meyts P., and Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1 (2002) 769-783
16. Moller D.E., Yokota A., Caro J.F., and Flier J.S. Tissue-specific expression of two alternatively spliced insulin receptor mRNA in man. Mol Endocrinol 3 (1989) 1263-1269
17. Soos M.A., Field C.E., Lammers R., et al. A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem 267 (1992) 12955-12963
18. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., and Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277 (2002) 39684-39695
19. Bailyes E.M., Bave B.T., Soos M.A., Orr S.R., Hayward A.C., and Siddle K. Insulin receptor/IGF-1 receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 327 (1997) 209-215
20. Pandini G., Vigneri R., Costantino A., et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5 (1999) 1935-1944
21. Papa V., Gliozzo B., Clark G.M., et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53 (1993) 3736-3740
22. Kull Jr. F.C., Jacobs S., Su Y.F., Svoboda M.E., Van Wyk J.J., and Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin C. J Biol Chem 258 (1983) 6561-6566
23. Soos M.A., Siddle K., Baron M.D., et al. Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. Biochem J 235 (1986) 199-208
24. Soos M.A., Field C.E., and Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290 (1993) 419-426
25. Soos M.A., and Siddle K. Immunological relationship between receptors for insulin and insulin-like growth factor-I. Evidence for structural heterogeneity of insulin-like growth factor-I receptors involving hybrids with insulin receptors. Biochem J 263 (1989) 553-563
26. Sciacca L., Mineo R., Pandini G., Murabito A., Vigneri R., and Belfiore A. In IGF-1 receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21 (2002) 8240-8250
27. Arteaga C.L., Kitten L.J., Coronado E.B., et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84 (1989) 1418-1423
28. Papa V., Pezzino V., Costantino A., et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 86 (1990) 1503-1510
29. Frasca F., Pandini G., Scalia P., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like-growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19 (1999) 3278-3288
30. Soos M.A., Whittaker J., Lammers R., Ullrich A., and Siddle K. Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 270 (1990) 383-390
31. Vella V., Sciacca L., Pandini G., et al. The IGF system in thyroid cancer: new concepts. J Clin Pathol Mol Pathol 54 (2001) 121-125
32. Vella V., Pandini G., Sciacca L., et al. A novel autocrine loop involving IGF-2 and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87 (2002) 245-254
33. Nielsen D., Gyllberg H., Ostlund P., Bergman T., and Bedecs K. Increased levels of insulin and insulin-like growth factor-1 hybrid receptors and decreased glycosylation of the insulin receptor alpha- and beta-subunits in scrapie-infected neuroblastoma N2a cells. Biochem J 380 (2004) 571-579
34. Hailey J., Maxwell E., Koukoulas K., Bishop W.R., Pachter J.A., and Wang Y. Neutralizing anti-insulin-like growth factor-1 receptor antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 1 (2002) 1349-1353
35. Sachdev D., Singh R., Fujita-Yamaguchi Y., and Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66 (2006) 2391-2402
36. Nahta R., Yuan L.X.H., Zhang B., Kobayashi R., and Esteva F.J. Insulin-like growth factor-1 receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 (2005) 11118-11128
37. Forsayeth J.R., Montemurro A., Maddux B.A., DePirro R., and Goldfine I.D. Effect of monoclonal antibodies on human insulin receptor autophosphorylation, negative cooperativity, and down-regulation. J Biol Chem 262 (1987) 4134-4140